East Hanover, N.J., Oct. 1, 2019 – Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Entresto (sacubitril/valsartan) for the treatment of symptomatic heart failure (HF) with systemic left ventricular…Original Article
FDA Approves Entresto (sacubitril/valsartan) for Pediatric Heart Failure
